*** In the 2014 Standards of Medical Care in Diabetes, the ADA states, "if non-insulin monotherapy at maximal tolerated dose does not achieve or maintain the A1c target over 3-6 months, add a second oral agent which would be?

a glucagon-like peptide (GLP-1) receptor agonist or insulin

*** What is the initial therapy recommended?

metformin

The American Assoc. of Clinical Endocrinologists recommends what as second-line therapy?

a GLP-1 receptor agonist or a DPP-4 inhibitor

A recent study further affirmed the benefit in hgbA1c reduction and low incidence of what?

adverse effects

In addition, the study suggested what other benefits with use of DPP-4 inhibitor therapy?

1) improvement in BP 2) improvement in lipid profile 3) improvement of quality of life